Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets

BACKGROUND: Effective glycemic control can reduce the risk of complications and their related costs in patients with type 2 diabetes (T2D). Many patients fail to reach hemoglobin A1c (HbA1c) ≤ 6.5% or < 7.0%, often due to adverse effects of treatment, such as hypoglycemia and weight gain. Glycemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannon, Anthony J., Bargiota, Alexandra, Billings, Liana, Hunt, Barnaby, Leiter, Lawrence A., Malkin, Samuel, Mocarski, Michelle, Ranthe, Mattis Flyvholm, Schiffman, Alisa, Doshi, Ankur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391176/
https://www.ncbi.nlm.nih.gov/pubmed/31856636
http://dx.doi.org/10.18553/jmcp.2019.19035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391176/
https://www.ncbi.nlm.nih.gov/pubmed/31856636
http://dx.doi.org/10.18553/jmcp.2019.19035

Ejemplares similares